Fig. 1
From: Cardiac tissue engineering: state-of-the-art methods and outlook
(1) Introduction of LQTS genes in independent healthy hPSC lines using CRISPR/Cas9. (2) Generation of disease-cardiomyocyte hiPSCs. (3) Isogenic sets of hPSC-CMs were differentiated from the edited hiPSCs lines. (4) Molecular analysis and phenotyping of hPSC-CMs (upper) molecular pathogenesis, (middle) drug screening, and (bottom) physiological functions